The use of artificial intelligence (AI) in clinical practice using immunotherapy to treat cancer (immuno-oncology) is still in its infancy. However, AI has potential for overcoming some of the current challenges in immuno-oncology. Professor Thomas Powles, St Bartholomew’s Hospital, London, and Professor Pedro Romero, UNIL Ludwig Institute for Cancer Research, Lausanne, Switzerland discussed the promises and challenges of integrating AI technologies into clinical practice during an educational session at the European Society of Medical Oncology (ESMO) Immuno-oncology Congress in Geneva last week.
Artificial intelligence and immuno-oncology
19 Dec 2019
Most used tags
renal cell carcinoma immunotherapy combination therapy checkpoint inhibitors Cancer nivolumab TKIs overall survival Opdivo sunitinib Sutent progression-free survival cabozantinib biomarkers NHS England Cabometyx ipilimumab pembrolizumab COVID-19 cancer survival axitinib VEGF inhibitors non-clear cell kidney cancer Inlyta coronavirus Yervoy risk factors Keytruda metastases adjuvant therapy biological markers papillary RCC targeted therapy everolimus Afinitor ASCO cancer outcomes first-line treatment NICE partial nephrectomyArchives
- 2023: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2022: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2021: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2020: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2019: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2018: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2017: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2016: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec